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I. ABSTRACT 
 
 
Background: A hallmark of the metabolic dysregulation associated with obesity is a pro-
inflammatory environment perpetuated by pro-inflammatory mediators including adipokines and 
growth factor signaling. We previously showed that inflammation and basal-like breast cancer 
(BLBC) growth are increased in chronically obese mice and these effects persist following 
significant weight loss. 
 
Hypothesis: We tested the hypothesis that Sulindac, a nonsteroidal anti-inflammatory drug 
(NSAID), can reduce chronic obesity-related inflammation and subsequent BLBC growth in 
mice. 
 
Methods: Mice were administered a control diet (10 kcal % fat) or diet-induced obesity regimen 
(DIO, 60 kcal % fat). After 15 weeks on diet, DIO mice either continued on DIO diet or were 
switched to the low fat control diet to induce gradual weight loss, resulting in Formerly Obese 
(FOB) mice. Half of the mice in all three groups (CON, FOB, DIO, n=20/group) were randomized 
to receive Sulindac supplementation at 160 ppm in the diet, which remained constant across 
diets. Ten weeks after initiating Sulindac supplementation and weight loss in the FOB groups, 
serum was collected via submandibular bleed on a subset of fasted mice (n = 10-12/group). 
Thereafter, all mice were orthotopically injected with E0771 cells, a model of BLBC. Five 
mice/group were killed 4 weeks after tumor cell injection, while 12 mice/group continued in a 
survival study; these mice were killed when tumor size reached 1.2 cm in diameter. An NF-κB 
signaling targets PCR array (Qiagen) was completed on mammary fat pad harvested at end of 
study.  
 
Results: Sulindac supplementation in DIO mice significantly reduced serum insulin and leptin to 
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levels statistically equivalent to both control and FOB mice. Interestingly, body weight and body 
fat percentage were unchanged between all supplemented and nonsupplemented counterparts 
(i.e. DIO vs. DIOSU). Sulindac supplementation in DIO mice (but not in CON or FOB mice) 
significantly reduced mean tumor volume relative to their nonsupplemented counterparts in the 
interim sac. Additionally, DIOSU had significantly increased percent survival compared to DIO, 
but no significant differences were observed in CON vs. CONSU or FOB vs. FOBSU. However, 
both FOB and FOBSU had significantly increased percent survival compared to DIO. The 
results of an NF-κB targets PCR array illustrated that Sulindac supplementation in DIO mice 
prevented losses in the expression of the NF-κB regulator TNF receptor-associated factor 2 
(TRAF2) and also decreased expression of the apoptosis regulator X-linked inhibitor of 
apoptosis (XIAP) and two additional inflammation-related genes: tumor necrosis factor (TNF) 
and colony stimulating factor 1 (CSF1).  
 
Conclusions: Sulindac supplementation significantly reduced the obesity-associated metabolic 
mediators insulin and leptin and decreased mammary tumor burden in DIO but not CON or FOB 
mice. Furthermore, Sulindac supplementation did not modulate body weight, and had no 
significant tumor effect in normal weight mice, suggesting that Sulindac indeed offsets some of 
the pro-tumorigeneic effects of obesity. Analysis of our PCR array of NF-κB targets suggests 
that Sulindac prevents altered expression of pro-inflammatory cytokines and anti-apoptosis 
genes.  Ongoing analyses of inflammatory surrogates, including circulating prostaglandins, 
mammary gland crown-like structures and cyclooxygenase-2 levels, will help to determine if 
Sulindac’s effects are mediated through its anti-inflammatory activity.  
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II. INTRODUCTION 
 
 
The prevalence of obesity has risen dramatically within the past 30 years. Today nearly 
40% of adults in the United States (U.S.) are considered obese [1]. The World Health 
Organization (WHO) estimates that 1.9 billion of the world’s population is overweight and 
another 600 million are obese, and these numbers continue to increase [2]. Overweight and 
obesity are characterized by excessive fat accumulation and classified by a weight-for-height 
index, commonly known as body mass index (BMI), with obesity defined as BMI ≥ 30 kg/m2. 
Must et al. [3] demonstrated a strong correlation between obesity and mortality risk that 
increases with advancing age. Given that life expectancy in the U.S. and other industrialized 
countries is on the rise, the now heavier and older population has a greater chance of 
experiencing the adverse health consequences of being overweight and obese [4]. 
Obesity engenders a state of chronic, low-grade inflammation characterized by 
excessive secretion of inflammatory mediators by adipocytes, macrophages, and other cells, 
including the gut microbiota. These pro-inflammatory factors disrupt metabolic homeostasis and 
thereby promote insulin resistance, type 2 diabetes, cardiovascular disease, genome instability 
and cancer [5]. The disparity in mortality between obese individuals and their lean counterparts 
is attributed, at least in part, to this aberrant pro-inflammatory signaling and the resulting 
metabolic dysfunction [6]. Unfortunately, significant and sustained weight loss is difficult to 
achieve in obese individuals. Thus, anti-inflammatory interventions such as prophylactic 
nonsteroidal anti-inflammatory (NSAID) use may be needed to reduce the inflammatory burden 
imposed with morbid adiposity levels. 
 Numerous clinical and epidemiological studies have shown beneficial health effects with 
increased supplementation of Sulindac, a nonsterodial anti-inflammatory drug (NSAID), 
including reductions in inflammation, hyperlipidemia and improved insulin signaling [7-9]. The 
anti-inflammatory and metabolic reprogramming properties of Sulindac have led to the 
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suggestion that Sulindac may reduce cancer risk and/or progression, although the effects of 
Sulindac in the context of obesity have not been evaluated.  
Obesity promotes an increased risk of many cancers and a worse cancer outcome after 
diagnosis. Obesity is an established risk factor for endometrial, colorectal, breast 
(postmenopausal), esophageal (adenocarcinoma subtype), liver, kidney, gallbladder, 
pancreatic, uterine, and ovarian cancer [10].  Obesity also worsens the prognosis of each of 
these cancers as well several others, including prostate cancer, premenopausal breast cancer, 
thyroid cancer, and some leukemias. Morbid obesity (BMI > 40 kg/m2) is associated with a 
markedly higher risk of dying from cancer, increasing rates by 52% in men and 62% in women 
[11]. The exact mechanisms underlying the obesity-cancer link remain unclear, but abundant 
evidence suggests that they involve increased adipose tissue inflammation and metabolic 
dysfunction.  
The local secretion of inflammatory adipocytokines from adipose tissue, including tumor 
necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β), resistin, and monocyte 
chemotactic protein-1 (MCP-1), is increased in obese individuals compared to their normal 
weight counterparts [12-14]. These pro-inflammatory cascades stem from an overabundance of 
immature pre-adipocytes, which recruit activated macrophages to the adipose tissue [15]. These 
adipose tissue macrophages (ATMs) are a primary source of pro-inflammatory cytokines, which 
are involved in paracrine and endocrine signaling and often have potent pro-tumor effects [15]. 
Cytokines promote tumor growth in the microenvironment by increasing angiogenesis and 
fostering an immunosuppressive environment, which works against the body’s anti-tumor 
immunity. IL-6 inhibits the maturation of dendritic cells, thus reducing the population of cytotoxic 
T-cells, which kill cancer cells [16]. IL-1β promotes tumor growth by inducing angiogenic factors, 
including vascular endothelial growth factor, which support the tumor with a nutrient rich blood 
supply [17].  These extracellular inflammatory and angiogenic signals can lead to intracellular 
activation of the transcription factor NF-κB through the phosphorylation of its upstream activator 
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IkB kinase-β (IKK-β), which induces increased gene expression of pro-inflammatory cytokines 
such as IL-6, TNF-α, and IL-1β. TNF-α is known to increase tumor cell proliferation, tumor 
stage, and systemic metastatic growth [18-19]. In addition, TNF-α and IKK-β activate c-Jun 
NH2-terminal kinase (JNK), which promotes proliferation and survival of tumor cells [20-21]. 
TNF-α also contributes to insulin resistance by increasing insulin receptor substrate 1 (IRS-1) 
phosphorylation at serine 307, which impairs its ability to initiate downstream signaling and 
consequently blocks the biological actions of insulin [22-23]. Like TNF-α, IL-6 also affects insulin 
signaling by inhibiting the gene transcription of IRS-1 and glucose transporter type 4 (GLUT-4), 
resulting in decreased insulin sensitivity [23]. Moreover, this increased secretion of cytokines 
from adipose tissue can further lead to genomic instability through the shortening of telomeres. 
Telomere shortening is widely accepted as a biological occurrence of accelerating aging and 
aging-related diseases such as cancer. This is mediated through increased oxidative stress, 
DNA damage, and telomere shortening activation of p53 and p21 that upregulates secretion of 
TNF-α and IL-6 further leading to insulin resistance. 
The adipokines leptin and adiponectin are primarily thought of as regulators of calorie 
intake and energy expenditure, however they are also involved in modulating inflammation and 
insulin resistance. Leptin signaling promotes satiety, thereby decreasing food intake. However, 
the onset of obesity causes individuals to become leptin resistant despite excess leptin 
production by the adipose tissue. In many obese individuals, leptin acts directly on 
macrophages to stimulate the synthesis of pro-inflammatory cytokines like TNF-α  and IL-6. 
Adiponectin acts as an antagonist to leptin’s pro-inflammatory effects in part by activating AMP-
dependent protein kinase (AMPK), which increases fatty acid oxidation and glucose uptake in 
skeletal muscle and decreased hepatic gluconeogenesis [24]. However, TNF-α, IL-6 and other 
pro-inflammatory mediators suppress adiponectin secretion from adipocytes, and the obese 
population typically has low adiponectin levels [24].  
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 Leptin secretion from adipocytes has been shown to induce tumor growth as well as 
cancer cell invasion and angiogenesis, suggesting the role of adipose tissue as a catalyst to 
cancer development and progression. Interestingly, leptin antagonist treatment reduces the 
growth of triple negative breast tumors in mice through decreased VEGF, pSTAT3, and cyclin 
D1 levels, highlighting leptin’s pro-carcinogenic potential [25]. Alternatively, clinical studies have 
shown circulating levels of adiponectin are inversely correlated with obesity-related 
malignancies such as breast cancer [25].. Adiponectin functions to decrease endothelial cell 
proliferation and migration, induce apoptosis, and decrease tumor vascularization. Clinically, the 
leptin:adiponectin ratio (L:A) is increasingly accepted as a biomarker for metabolic syndrome 
[25]. Additionally, in colorectal cancer patients the L:A ratio is as much as eight fold greater 
compared to cancer-free controls and also serves as an independent predictor for adverse 
outcomes in colorectal cancer [26].  
High BMI levels are associated with increased insulin secretion, leading to 
hyperinsulinemia. This metabolic dysfunction contributes to the decreased insulin sensitivity that 
is also induced by obesity-associated chronic inflammation. Elevated levels of insulin have been 
associated with cancer progression through insulin-like growth factor-1 (IGF-1) signaling. 
Increased circulating levels of IGF-1 have been correlated with increased risk of prostate, 
breast, and colorectal cancer [27]. Insulin itself is thought to have anti-inflammatory effects in 
healthy individuals, as it can decrease reactive oxygen species (ROS) in mononuclear cells and 
suppress MCP-1 and plasminogen activator inhibitor-1 (PAI-1) levels and intranuclear NF-κB 
binding [28-32]. Thus, adequate insulin signaling is needed to repair the inflammatory state of 
obesity, otherwise continuous secretion of TNF-α, IL-6, and C-reactive protein (CRP) will occur 
[33]. 
A hallmark of the metabolic dysregulation associated with obesity is a pro-inflammatory 
environment perpetuated by pro-inflammatory mediators including adipokines and growth factor 
signaling. Sulindac mediates inflammatory signaling through inhibition of cyclooxygenases 
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(COXs) specifically COX-2 which are known to induce secretion of prostaglandins and 
thromboxanes. The anti-cancer effect of Sulindac is illustrated through its ability to decrease 
activity of COX-2, which is often over-expressed in cancerous tissues and results in 
carcinogenesis as well as dysfunctional apoptosis and inhibition of tumor growth in various 
studies of breast, colon and, ovarian cancer [34-36]. Sulindac’s chemopreventive effects are 
also regulated through its ability to inhibit the activation of cellular stress pathways such as the 
NF-κB pathway by decreasing IKKβ activity [37]. In vitro work has shown that stimulation of NF-
κB pathway induces anti-apoptotic genes such as cellular inhibitor of apoptosis-1 and -2, which 
block regulation of apoptosis and further increases cell growth and proliferation [38-39]. 
Therefore it is likely Sulindac in vivo could provide its host with a wide range of metabolic 
benefits, including decreased systemic inflammation and sustained apoptosis, which would 
provide an anti-cancer benefit.  
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III. SPECIFIC AIMS, HYPOTHESIS  
 
 
The current world population has an unprecedented risk of dying from the consequences 
of being overweight and obese. Chronic diseases such as cardiovascular disease, type 2 
diabetes, and cancer are often accelerated because of excess adiposity. Various biological 
mechanisms are implicated in the obesity-cancer link, particularly local and systemic 
inflammation as well as altered growth factor signaling pathways. In order to combat obesity-
induced inflammation and the resulting increases in cancer risk and progression, mechanistic 
anti-inflammatory targets are imperative. Notably, nonsteroidal anti-inflammatory drugs 
(NSAIDS) such as Sulindac, can modulate the secretion of pro-inflammatory cytokines such as 
tumor necrosis factor alpha and interleukin-6, restore insulin sensitivity, and can prevent or 
delay tumorigenesis. Delineating the precise mechanisms by which Sulindac suppress obesity-
induced inflammation will help identify promising key targets for clinical application to break the 
obesity-cancer link.  
We have previously shown that inflammation and basal-like breast cancer (BLBC) 
growth are increased in chronically obese mice and persist following weight normalization. 
Weight normalization to levels equivalent of mice never exposed to an obesity-inducing regimen 
(obesity reversal) failed to normalize obesity-associated tumor burden, methylation patterns, 
and mRNA expression of pro-inflammatory mediators such as IL-6 and TNF-α relative to control 
mice. Thus, significant weight loss was not sufficient to reverse the effects of chronic obesity on 
epigenetic reprogramming and inflammatory signals in the microenvironment in association with 
breast cancer progression [40]. This study seeks to complement weight loss with Sulindac 
supplementation and determine its mechanism in offsetting the procancer effects of obesity and 
subsequent inflammation. 
 
 
Increased Mammary 
Tumor Progression Obesity Inflammation 
Sulindac 
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Aim 1: Identify whether mechanistic anti-inflammatory interventions such as Sulindac 
supplementation can reduce chronic obesity-related inflammation and/or basal-like 
tumor growth.  
 
Aim 2: Determine whether Sulindac’s effects are exclusive to obesity or if it could 
complement weight loss in formerly obese mice to more effectively reduce residual 
inflammation and/or basal-like tumor growth. 
 
Aim 3: Identify the effects of Sulindac supplementation on key proponents of pro-growth 
and inflammatory obesity-associated mediators including the targets of the nuclear-
factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway.  
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IV. Methods 
 
 
Animal Study Design: Housing, Diet, and Care 
 
All animal protocols were approved and coordinated with all compliance and guidelines by the 
University of North Carolina at Chapel Hill Institutional Care and Use Committee (IACUC). One 
hundred and eighteen female 6-8 week old C57BL/6 mice (an obesity-responsive mouse model) 
were obtained from Charles River Laboratories International, Inc. (Wilmington, MA). Upon 
arrival mice were housed three per cage on a 12-hour light/dark cycle with food and water 
consumption ad libitum. Standard chow was given to all mice for one week in order to acclimate. 
Post-acclimation, mice were randomized to two groups, either receiving a control (CON; 10% 
kcal from fat) diet (n=40; Product # D12450J; Research Diets, Inc.) or a diet-induced obesity 
(DIO; 60% kcal from fat) regimen (n=99; Product # D12492; Research Diets, Inc.) in order to 
model chronic obesity. Body weight and food intake were measured weekly. After 15 weeks on 
diet, with the weights of both the CON and DIO mice statistically significant from each other (p < 
0.001), a subset of control mice (n = 20) were supplemented with Sulindac (160 ppm, equivalent 
to 160 mg Sulindac per kg of food) while the rest (n=20) remained on the control diet alone. DIO 
mice either continued on the DIO diet with (n = 20) or without (n = 19) Sulindac supplementation 
or were switched to the low fat control diet with (n = 20) or without (n = 20) Sulindac to induce 
gradual weight loss, resulting in Formerly Obese mice (FOB) mice. The resulting groups of mice 
are as follows: control (CON), control + Sulindac (CONSU), formerly obese (FOB), formerly 
obese + Sulindac (FOBSU), diet induced obesity (DIO), and diet induced obesity + Sulindac 
(DIOSU). After 27 weeks on diet and when all weights were stabilized, all mice were 
orthotopically injected with 3.5 x 104 E0771 mammary tumor cells into the 4th mammary fat pad 
(Figure 1). In vivo tumor growth was measured two times per week with skinfold calipers and in 
vivo tumor area was determined using the formula πr2.  Four weeks later, a subset of mice (n = 
5/diet group) was killed due to tumor diameter reaching 1.0 cm in any direction (interim sac). 
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Blood was collected by cardiac puncture, allowed to clot at room temperature for 30 minutes 
and centrifuged for 10 minutes at 1000 x g to isolate serum, and stored at -80°C. Mammary 
tumors, tumor-adjacent and tumor-distal mammary fat pad were excised and sectioned to either 
be formalin fixed or flash frozen in liquid nitrogen and stored at -80°C until further analysis. All 
remaining mice, (n=12/diet group) were followed for tumor-free survival; non-mammary tumor-
related deaths were censored. When the tumors reached 1.2 cm in any direction, mice were 
killed (week 50) and blood, mammary tumor, and tumor-adjacent and tumor-distal mammary fat 
pad were collected as previously described. Ex vivo tumor volume was calculated using the 
formula 1/6π x D1 x D2 x D3 (where D is equal to ex vivo diameter of the tumor). End of study 
blood was collected by cardiac puncture, allowed to clot at room temperature for 30 minutes and 
centrifuged for 10 minutes at 1000 x g to isolate serum, and stored at -80°C. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Dietary energy modulation affects body weight indiscriminant of Sulindac 
supplementation in CON, CONSU, FOB, and FOBSU vs. DIO and DIOSU. Differences in 
significance noted by different letters (a,b); p-value < 0.05. 
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E0771 Basal-like Mammary Tumor Cells  
E0771 cells were purchased from CH3 BioSystems (Catalog # 940001; Amherst, NY). These 
syngeneic mammary tumor cells model basal like breast cancer and were originally isolated 
from a spontaneous medullary breast adenocarcinoma in a C57BL/6 mouse [41] and adapted 
by Sirotnak et al. (1984) for chemotherapeutic experimentation [42]. 
 
Quantitative Magnetic Resonance Imaging Analysis 
Quantitative magnetic resonance imaging (qMRI) (Echo Medical Systems, Houston, TX) was 
used to determine body composition for all groups (n = 9-10 mice/group) at end of study. The 
three components of total mass: lean, fat, and free water were quantified. Additionally, body 
weight was measured with a digital scale and used to calculate body fat percentage with qMRI 
data.  
 
Metabolic Analysis of Serum Hormone, Cytokine, and Adipokine  
Prior to tumor injections (week 27), serum was collected from mice fasted 4-6 hours (n = 10-
12/group) via submandibular bleed. Serum hormones, adipokines, and cytokines including 
insulin, leptin, adiponectin, IL-6 and resistin, were measured using Bio-Plex ProTM Mouse 
Diabetes Panel 8-Plex, Mouse Diabetes Adiponectin Assay, and Mouse Cytokine Panel A 6-
Plex, respectively (Bio-Rad Laboratories; Hercules, California). Insulin-like growth factor 1 (IGF-
1) concentrations were measured using R & D systems IGF-1 Bead-Based Single-plex Luminex 
assay (Minneapolis, MN).  
 
Quantitative NF-κB Signaling Targets RT-PCR Array and RT-PCR of HIF-1α and Insulin 
Receptor (IR) 
Total RNA was extracted from the homogenized flash-frozen distal mammary fat pad samples 
collected at end of study using TRI-Reagent (Sigma-Aldrich, St. Louis, MO) according to 
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manufacturer’s instructions. RNA concentration was spectrophotometrically determined using a 
nanodrop (Thermo Scientific, Logan, UT). Samples were prepared and plated according to 
Qiagen’s NF-κB Signaling Targets PCR Array protocol (Foster City, California). PCR reactions 
were completed using a ViiATM7 Real Time PCR system (Applied Biosciences, Carlsbad, CA). 
Gene expression was normalized to the housekeeping genes β-actin, β-2 microglobulin (β-2M), 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and β-glucuronidase (β-GUS). Results 
were analyzed using Qiagen RT Profiler data analysis software (Catalog no. PAMM-225Z). For 
rt-PCR as a follow up to the array, additional RNA was reverse transcribed with Multiscribe RT 
(Applied Biosystems) and cDNA were assayed separately in triplicate for PCR using Taqman® 
Gene Expression Assays for hypoxia-inducible factor-1α (HIF-1 α) and insulin receptor (IR) 
(Applied Biosystems). PCR reactions were completed using a ViiATM7 Real Time PCR system 
(Applied Biosciences). Gene expression was normalized to the housekeeping gene β-actin and 
analyzed using the delta delta cycle threshold method [43]. 
 
Quantification of Adipocyte Infiltration in Tumor Tissue 
A four micron-thick section was prepared from formalin-fixed, paraffin-embedded tumor tissue 
and stained with hematoxylin and eosin for all groups. Tumors were selected at random (n=5-
6/group) and digitally imaged under 40X magnification using Aperio Digital Pathology Slide 
Scanners. The total area of adipocytes per section (3 representative sections, each 400 µm x 
400 µm) was quantified using Adobe Photoshop 3.0.  
 
Statistical Analysis 
All values are represented as mean ± standard deviation (STDEV). One-way analysis of 
variance (ANOVA) using Tukey’s multiple comparisons correction was used to assess the 
effects of diet regimen on body weight and fat percentage, mean tumor volume, serum hormone 
and cytokine concentrations and mammary fat pad gene expression. Log-rank (Mantel-Cox) 
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was utilized to determine the effect of Sulindac supplementation on survival. Results were 
analyzed using GraphPad Prism software (Graphpad Software Inc., La Jolla, CA) and p ≤ 0.05 
was considered statistically significant.   
 18 
V. Results 
 
Body Weight and Body Composition of CON, FOB, and DIO mice +/- Sulindac 
Supplementation 
Mice were fed a low fat (control) or a diet-induced obesity (DIO) regimen for 15 weeks in order 
to establish a lean/control or obese phenotype. Body weights between CON and DIO mice 
achieved statistical significance at week 3 and continued throughout study (p < 0.001). At end of 
study, body fat percentage was assessed by quantitative magnetic resonance imaging analysis 
and was significantly higher in DIO (53.9 ± 4.18) and DIOSU (45.5 ± 5.65) mice compared to 
CON (20.1 ± 8.26), CONSU (17.6 ± 4.57), FOB (40.0 ± 7.08), and FOBSU (22.5 ± 7.47) mice 
(Table 1). FOB mice also had statistically higher body fat percentage relative to CON and 
CONSU mice and intermediate levels illustrated in FOBSU mice (Supplementary Figure 1A). 
 
Table 1. qMRI body fat percentage results of significance across diet groups with or without 
Sulindac supplementation (NS = not significant). 
 
B
od
y 
Fa
t (
%
)  CON CONSU FOB FOBSU DIO DIOSU 
CON   
CONSU NS  
FOB NS p < 0.001  
FOBSU NS NS NS  
DIO p < 0.0001 p < 0.0001 p < 0.0001 p < 0.0001  
DIOSU p < 0.0001 p < 0.0001 p < 0.001 p < 0.0001 NS  
 
 
Effects of Sulindac on Serum Metabolic Hormones, Pro-Inflammatory Cytokines and 
Gene Expression in the Microenvironment 
When weights were stabilized in FOB and FOBSU mice (week 24, 9 weeks after diet switch), 
FOB and FOBSU mice had statistically equivalent body weights compared to CON and CONSU 
mice, serum was collected from a subset of fasted mice via submandibular bleed (n=10-
12/group). Insulin levels in CONSU were significantly lower compared to FOB, DIO, and DIOSU 
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(Table 2) with intermediate levels that were not significantly different in CON and FOBSU mice. 
DIOSU mice experienced a modest but not significant decrease in insulin levels compared to 
DIO mice. However, CON, CONSU, and FOBSU possessed statistically equivalent levels of 
insulin-like growth factor 1 (IGF-1), which were all significantly lower than DIO mice (Table 2). 
FOB and DIOSU mice illustrated intermediate IGF-1 levels in comparison to the rest of the 
groups. Moreover, leptin (Table 2) was significantly reduced in DIOSU vs. DIO mice and this 
was also correlated to a significant decrease in the leptin to adiponectin ratio in DIOSU vs. DIO 
mice (Supplementary Figure 1D). However, no significant relationships were illustrated in 
adiponectin levels between all diet groups (Table 2). IL-6 concentrations did not differ between 
diet groups, partially due to high variability within groups (data not shown). Lastly, levels of 
adipose tissue-specific secretory factor (ADSF) resistin were higher but not significant in DIO 
and DIOSU mice relative to CON and FOB mice with or without Sulindac supplementation (data 
not shown).  
 
Moreover, RNA extracted from the distal mammary fad illustrated varied differences in the 
relative gene expression of HIF-1α and insulin receptor (IR). CONSU, FOB, and FOBSU had 
significant reductions in HIF-1α gene expression levels relative to DIO mice (Supplementary 
Figure 1E). CON and DIO displayed intermediate but reduced levels of HIF-1α in comparison to 
DIO mice. IR relative gene expression was modestly elevated but not significant in all of the 
Sulindac supplemented groups compared to their nonsupplemented counterpart 
(Supplementary Figure 1F). 
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Table 2. Summary results of serum metabolic hormone concentrations between diet groups 
with or without Sulindac supplementation. Data presented as mean ± STDEV; NS=not 
significant.  
 
In
su
lin
 
(n
g 
/ m
L)
 
 Average ±  
STDEV CON CONSU FOB FOBSU DIO DIOSU 
CON 189.9 ± 48.2  
CONSU 118.3 ± 50.28 NS  
FOB 255.7± 87.17 NS p < 0.01  
FOBSU 199.2 ± 64.4 NS NS NS  
DIO 316.0 ± 109.8 p < 0.05 p < 0.0001 NS p < 0.05  
DIOSU 235.2 ± 50.4 NS p < 0.05 NS NS NS  
 
IG
F-
1 
(n
g 
/ m
L)
 
 Average ±  
STDEV CON CONSU FOB FOBSU DIO DIOSU 
CON 83.7 ± 26.7  
CONSU 74.9 ± 27.7 NS  
FOB 118.5 ± 38.9 NS NS  
FOBSU 80.1 ± 23.4 NS NS NS  
DIO 134.3 ± 42.9 p < 0.05 p < 0.05 NS p < 0.01  
DIOSU 103.3 ± 17.5 NS NS NS NS NS  
 
Le
pt
in
 
(n
g 
/ m
L)
 
 Average ±  
STDEV CON CONSU FOB FOBSU DIO DIOSU 
CON 2.81 ± 2.11  
CONSU 1.71 ± 1.29 NS  
FOB 4.56 ± 2.85 NS NS  
FOBSU 1.87 ± 1.12 NS NS NS  
DIO 17.1 ± 10.8 p < 0.0001 p < 0.0001 p < 0.0001 p < 0.0001  
DIOSU 9.52 ± 4.23 NS p < 0.05 NS p < 0.05 p < 0.05  
A
di
po
ne
ct
in
 
(n
g 
/ µ
L)
 
 Average ±  
STDEV CON CONSU FOB FOBSU DIO DIOSU 
CON 10.6 ± 2.14  
CONSU 12.2 ± 4.57 NS  
FOB 10.9 ± 2.35 NS NS  
FOBSU 10.6 ± 1.69 NS NS NS  
DIO 9.70 ± 2.28 NS NS NS NS  
DIOSU 12.2 ± 2.77 NS NS NS NS NS  
 
 
Sulindac Impacts Ex Vivo Tumor Volume in DIO Mice at Interim Sac and Tumor-free 
Survival 
Sulindac supplementation in DIO mice blunted tumor growth compared to DIO mice. Tumor 
volume at interim sac illustrated a significant reduction in DIO mice supplemented with Sulindac 
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(Supplementary Figure 2A). DIO mice had the largest and fastest growing tumors, with ex vivo 
volume at the interim sac being significantly greater than CON, CONSU, FOB, FOBSU, and 
DIOSU. In the survival portion of the study, DIO mice supplemented with Sulindac experienced 
significantly (p < 0.05) prolonged time of death due to slower tumor growth in comparison to 
nonsupplemented DIO mice (Figure 2). FOBSU mice had moderately longer but not significant 
tumor-free survival than FOB mice (Table 3). 
 
Figure 2. DIO mice supplemented with Sulindac experienced significantly (p < 0.05) prolonged 
time of death due to slower tumor growth in comparison to nonsupplemented DIO mice. 
 
Table 3. Comparison of tumor-free survival across all diet groups with or without Sulindac 
supplementation (NS=not significant). 
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Sulindac Decreases Infiltrated Adipocytes into the Mammary Tumor 
 
Sulindac effects adipocyte infiltration into the mammary tumor. CON, CONSU, FOB, and 
FOBSU average adipocyte area was significantly reduced compared to DIO mice 
(Supplementary Figure 2B). DIOSU mice portrayed intermediate levels of adipocyte area in the 
mammary tumor that was not significantly different from the remaining groups. H & E staining of 
mammary tumors also illustrated larger adipocytes in the DIO mice not supplemented with 
Sulindac (Supplementary Figure 2C) compared to DIOSU mice. 
 
Sulindac Modulates Altered Gene Expression as Depicted in an NF-κB Signaling Targets 
PCR Array 
Heat map representation of all diet groups compared to CON mice and altered inflammatory 
gene signaling was seen in the Sulindac supplemented groups where differences in color 
represents gene upregulation (green) and gene downregulation (red). Significant upregulated 
and downregulated genes in DIOSU were entered into Qiagen’s Ingenuity® Pathway Analysis 
(IPA) to determine pathological signaling pathways modulated by Sulindac supplementation in 
DIO mice. Upregulation of apoptotic genes and downregulation of inflammatory genes such as 
IL-1β and NF-κB2 were illustrated in DIOSU mice relative to DIO mice (Supplementary Figure 
3).  
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VI. DISCUSSION  
 
The results of this study illustrate the ability of Sulindac supplementation to be an 
effective strategy to offset the pro-inflammatory environment induced by obesity, which in turn 
can reduce subsequent mammary tumor development. Interestingly, body weight and body fat 
percentage were unchanged between all supplemented and nonsupplemented counterparts (i.e. 
DIO vs. DIOSU). We observed Sulindac’s effects in blunting obesity-associated metabolic 
dysfunction in the serum and microenvironment through a significant reduction in serum insulin 
and leptin in DIOSU to levels statistically equivalent to both CON and FOB mice with or without 
Sulindac. CON, FOB, and DIO mice supplemented with Sulindac experienced modest 
decreases in IGF-1 levels. CON, FOB, DIO mice supplemented with Sulindac illustrated 
reductions in Leptin:Adiponectin with a significant reduction in DIOSU vs. DIO. DIOSU mice also 
had decreased HIF-1α and increased insulin receptor (IR) relative gene expression in the 
mammary fat pad compared to its nonsupplemented counterpart.  
Furthermore, DIO mice supplemented with Sulindac illustrated decreases in obesity-
induced mammary tumor burden through reductions in ex vivo tumor volume and increased 
percent survival, indicative of slower growing tumors. Sulindac supplementation in DIO mice 
(but not in CON or FOB mice) significantly reduced mean tumor volume relative to their 
nonsupplemented counterparts. Quantified adipocyte infiltration into the mammary tumor 
portrayed Sulindac’s ability in DIO mice to decrease average adipocyte area to levels seen in 
CON or FOB mice with or without Sulindac supplementation. Moreover, NF-κB signaling targets 
array results suggests that Sulindac prevents altered expression of cytokines and anti-apoptosis 
genes. Sulindac supplementation in DIO mice prevented losses in the expression of NF-κB 
regulator TNF receptor-associated factor 2 (TRAF2) and also decreased expression of 
apoptosis regulator X-linked inhibitor of apoptosis (XIAP) and inflammatory related genes, tumor 
necrosis factor (TNF) and colony stimulating factor (CSF1). In the survival arm of the study, 
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Sulindac significantly increased percent survival defined as time until one dimension of the 
tumor was 1.2 cm, requiring euthanization in DIO and FOB groups (but not CON and CONSU) 
in comparison to their nonsupplemented counterparts.  
 The anti-inflammatory properties of Sulindac was profoundly pronounced in DIO mice 
with reductions in IGF-1 and insulin levels, decreased tumor burden and tumor adipocyte 
infiltration, altered NF-κB pro-inflammatory signaling, and prolonged tumor-free survival. Future 
directions will consist of ongoing analysis of circulating prostaglandins, mammary gland crown-
like structures and cyclooxgease-2 levels in order to further determine if Sulindac’s effects are 
mediated through its anti-inflammatory activity in reducing the procancer effects of obesity. 
Furthermore, in collaboration with Dr. Andrew Dannenberg, we will determine the intersection 
between mouse to human concordance between obese women and mice supplemented with 
Sulindac and whether Sulindac can negate the pro-inflammatory factors that lead to local and 
systemic inflammation in promoting subsequent tumor burden. In summary, delineating the role 
and precise mechanisms of Sulindac in suppressing obesity-induced inflammation will help 
identify promising key targets to break the obesity-cancer link.  
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Supplementary Figures: 
 
 
 
 
Supplementary Figure 1: Sulindac blunts obesity-associated metabolic dysregulation in the 
serum and microenvironment. CON, FOB, and DIO mice supplemented with Sulindac 
experienced modest decreases in (A) Body fat %, (B) Insulin and (C) IGF-1. CON and FOB, 
but not DIO mice experienced reductions in (D) Leptin: Adiponectin. DIOSU mice also had 
decreased (E) HIF-1α and increased (F) Insulin receptor (IR) relative gene expression in the 
mammary fat fad vs. DIO. For Luminex serum analysis (A-D; n = 10-12/group) and for PCR 
analysis of mammary fat pad (E-F; n = 5-7/group). Data presented as mean ± STDEV. 
Differences in significance noted by different letters (a,b); p-value < 0.05. 
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Supplementary Figure 2: Sulindac supplementation decreases obesity-associated increases in 
mammary tumor growth in obese mice. (A) Sulindac supplementation blunts ex vivo tumor 
burden and (B) decreases average adipocyte area infiltrated in the mammary tumor to non-
obese levels compared to its nonsupplemented counterpart. (C) Representative images of 
adipocyte infiltration into the tumors of mice with or without Sulindac supplementation. Data 
presented as mean ± STDEV. Differences in significance noted by different letters (a,b); p-value 
< 0.05; Magnification: 400 µm. 
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Supplementary Figure 3: Heat map representation of gene expression in distal mammary fat 
pad (n= 4-6 mice/group). Differences in colors represents gene upregulation (green) and/or 
downregulation (red) relative to control. Sulindac supplementation in obese mice increases 
expression of regulators of apoptosis and inflammatory cytokines to decrease activation of the 
NF-κB signaling pathway. Regulation of growth and inflammatory gene signaling in DIOSU 
mice, expression quantified by NF-κB signaling targets array (Qiagen). Relationships predicted 
by IPA software.  
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